source
- Nurix halts development of BTK degrader zelebrudomide after phase 1 reviewNurix announced it will discontinue clinical development of its BTK degrader zelebrudomide, also known as NX-2127, following completion of enrollment in a phase 1 trial for aggressive non‑Hodgkin l…
- Pan Pepín recalls Para Bien Al Grano cereal batches over undeclared sesame allergenPan Pepín Inc., based in Bayamón, Puerto Rico, issued a voluntary recall of certain lots of its Para Bien Al Grano product after discovering that sesame, an undeclared allergen, is present. The co…